To cite this paper use one of the standards below:
Please log in to watch the video
Log inBackground: Inflammatory bowel diseases (IBDs), such as Crohn’s disease (CD) and ulcerative colitis (UC), are chronic, immune-mediated gastrointestinal disorders with increasing incidence in Brazil. Although genetic predisposition contributes to their etiology, environmental and psychosocial factors, such as adverse childhood experiences (ACEs), have been associated with an increased risk of these diseases. From an epigenetic perspective, such early life stress experiences may determine how certain genes are regulated, with DNA methylation being one of the most well-documented epigenetic regulatory mechanisms. However, little is still known about how DNA methylation is associated with IBDs. Aim: The goal of this pilot project was to identify, among twelve genes related to IBDs, the most promising targets for DNA methylation analysis in patients with UC and CD, exploring their association with ACEs. Methodology: Genomic DNA was extracted from peripheral blood of patients with CD, UC, and controls and subsequently quantified by nanospectrophotometry. After sodium bisulfite conversion, DNA was PCR-amplified and subjected to pyrosequencing on the PyroMark Q48 Autoprep (Qiagen). Primers were designed using PyroMark Assay Design to cover CpG sites of interest in genes NLRP3, NLRC4, ULK1, MUC1, hTERT, PANX1, GJA4, CDKN2A, APC, TNFRSF1B, WNT5A and MLH1. Results: Genes with the best performance in PCR and sequencing steps in two independent tests were selected. The genes NLRP3, NLRC4, ULK1, MUC1, MLH1, CDKN2A, and APC showed satisfactory results and were retained. The gene TNFRSF1B was included with reservations due to the need for sequence adjustment. The genes GJA4, PANX1, hTERT, and WNT5A had amplification failures or unsatisfactory sequencing and were therefore excluded. Conclusion: We verified that the implementation of the pyrosequencing technique was successful, enabling precise quantification of the methylation percentage at the CpG sites of interest. Thus, it was possible to select the most promising genes for the subsequent analyses of the project.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper